Development of A Multi-Modality System for Onco-Imaging

肿瘤成像多模态系统的开发

• 批准号: 7665201
• 负责人: GULTEKIN GULSEN
• 金额: $ 48.15万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-08-01 至 2011-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7665201
• 关键词: Academia; Animals; Benign; Clinical Trials; Collaborations; Contrast Media; Detection; Development; Ethylnitrosourea; Frequencies; Future; Hemoglobin; Human; Hybrids; Image; Industry; Kinetics; Magnetic Resonance Imaging; Malignant - descriptor; Measures; Modality; Modification; Molecular; Molecular Probes; Molecular Weight; Mono-S; Optical Tomography; Optics; Outcome; Phase; Polymers; Property; Research; Role; Specificity; System; Technology; Testing; base; bioimaging; cancer diagnosis; design; extracellular; novel; optical imaging; size; technology development; tissue oxygenation; tool; tumor

DESCRIPTION (provided by applicant): Recently, the optical imaging field has been rapidly expanding in scope through the use of new exogenous molecular probes. We have already developed a multi-frequency & multi- spectral optical tomography animal imaging system and integrated to an MRI system. In this application, we will expand our hybrid system to measure dynamic information from exogenous probes. This system would measure the enhancement kinetics of the bi-functional MR/NIR or mono-functional NIR contrast agents in addition to the endogenous contrast due to hemoglobin contents and scattering properties. There are two main phases of the proposal. The first and the foremost phase is the technology development, which can be classified into two sub aims: a) the development of a novel multi-modality dynamic imaging system and b) the development of polymer based bi-functional and mono-functional NIR agents. We believe that such a hybrid system will facilitate the development of new contrast agents for biomedical imaging and that the development of polymer based molecular agents will provide a potential new molecular platform for these new contrast agents. In the second phase of the proposal, we will try to utilize this novel hybrid system together with a small molecular MR and a medium size (~30-40 kDa) novel polymer based optical agent. We will compare the role of all kinetic parameters and intrinsic properties obtained by MR/Optical imaging system, individually or combined, in cancer diagnosis after completing all analysis steps. Thus, we will be able to test our hypothesis that "the parameters obtained by macromolecular optical agent together with total hemoglobin, oxygen saturation and tissue scattering parameters can achieve a higher specificity in differentiating between ENU induced malignant and benign tumors compared to MRI parameters measured by low molecular weight extracellular MRI agents". We believe our collaboration with GE Global Research Center for the development of the novel MR/NIR contrast agents will serve to close the gap between the academia and the industries further for biomedical imaging applications. If successful, the outcome of our effort will offer a sophisticated tool that could provide high sensitivity and high specificity in the detection and characterization of tumors. With appropriate modifications in design, the proposed MR/Optical technology has a great translational potential for future human clinical trials. This application is aimed at developing a hybrid MR/DOT system along with novel polymer based contrast agents. If successful, the outcome of our effort will offer a sophisticated tool that could provide high sensitivity and high specificity in the detection and characterization of tumors.

描述（由申请人提供）：最近，通过使用新的外源分子探针，光学成像场在范围中迅速扩大。我们已经开发了多频和多光谱光学断层扫描动物成像系统，并集成到MRI系统。在此应用中，我们将扩展混合系统，以测量外源探针的动态信息。该系统还将测量由于血红蛋白含量和散射特性引起的内源性对比度外，双功能MR/NIR或单功能性NIR对比剂的增强动力学。该提案有两个主要阶段。第一阶段也是最重要的是技术开发，可以将其分为两个子目的：a）新型多模式动态成像系统的开发以及b）基于聚合物的双功能和单功能NIR代理的开发。我们认为，这种混合系统将有助于开发新的生物医学成像对比剂，并且基于聚合物的分子剂的开发将为这些新的对比剂提供潜在的新分子平台。在该提案的第二阶段，我们将尝试利用这种新型混合系统，以及一个小的分子MR和中等大小（〜30-40 kDa）基于新型聚合物的光学剂。我们将比较完成所有分析步骤后，在MR/光学成像系统（单独或组合）中通过MR/光学成像系统获得的所有动力学参数和固有特性的作用。因此，我们将能够检验我们的假设：“与总血红蛋白，氧饱和度和组织散射参数相比，与通过低分子量互联物界面MRI相比，与ENU诱导的恶性肿瘤和MRI参数相比，与ENU诱导的恶性肿瘤和MRI参数相比，可以在区分ENU诱导的恶性肿瘤和MRI参数方面获得更高的特异性。我们认为，我们与GE全球研究中心的合作新小说MR/NIR对比代理商将进一步缩小学术界与行业之间的差距，以实现生物医学成像应用。如果成功的话，我们的努力结果将提供一个复杂的工具，可以在肿瘤的检测和表征中提供高灵敏度和高特异性。在设计方面进行了适当的修改，拟议的MR/光学技术具有未来人类临床试验的巨大转化潜力。该应用旨在开发混合MR/DOT系统以及新型聚合物的对比剂。如果成功的话，我们的努力结果将提供一个复杂的工具，可以在肿瘤的检测和表征中提供高灵敏度和高特异性。